Literature DB >> 32426207

COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series.

Richard Hughes1, Rosetta Pedotti2, Harold Koendgen2.   

Abstract

Year:  2020        PMID: 32426207      PMCID: PMC7228884          DOI: 10.1016/j.msard.2020.102192

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  8 in total

1.  Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.

Authors:  Wallace Brownlee; Dennis Bourdette; Simon Broadley; Joep Killestein; Olga Ciccarelli
Journal:  Neurology       Date:  2020-04-02       Impact factor: 9.910

2.  Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.

Authors:  Gavin Giovannoni
Journal:  Mult Scler Relat Disord       Date:  2020-04-18       Impact factor: 4.339

3.  Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.

Authors:  Rebecca Haberman; Jordan Axelrad; Alan Chen; Rochelle Castillo; Di Yan; Peter Izmirly; Andrea Neimann; Samrachana Adhikari; David Hudesman; Jose U Scher
Journal:  N Engl J Med       Date:  2020-04-29       Impact factor: 91.245

4.  An Italian programme for COVID-19 infection in multiple sclerosis.

Authors:  Maria Pia Sormani
Journal:  Lancet Neurol       Date:  2020-04-30       Impact factor: 44.182

5.  COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

Authors:  Giovanni Novi; Malgorzata Mikulska; Federica Briano; Federica Toscanini; Francesco Tazza; Antonio Uccelli; Matilde Inglese
Journal:  Mult Scler Relat Disord       Date:  2020-04-15       Impact factor: 4.339

6.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

7.  The COVID-19 pandemic and the use of MS disease-modifying therapies.

Authors:  Gavin Giovannoni; Chris Hawkes; Jeannette Lechner-Scott; Michael Levy; Emmanuelle Waubant; Julian Gold
Journal:  Mult Scler Relat Disord       Date:  2020-03-27       Impact factor: 4.339

8.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.